

# Stefania Landolfi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2902450/publications.pdf>

Version: 2024-02-01

66  
papers

4,531  
citations

201674

27  
h-index

155660

55  
g-index

69  
all docs

69  
docs citations

69  
times ranked

8824  
citing authors

#	ARTICLE	IF	CITATIONS
1	European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United European Gastroenterology Journal, 2021, 9, 13-37.	3.8	122
2	miRNA landscape in primary tumors and matched metastases in gastrointestinal stromal tumors. Epigenomics, 2021, 13, 369-377.	2.1	2
3	Young-onset colorectal cancer: A call for action.. Journal of Clinical Oncology, 2021, 39, 10563-10563.	1.6	1
4	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor – an update on neuroendocrine neoplasms' treatment: A case report. World Journal of Hepatology, 2021, 13, 611-619.	2.0	0
5	Quantifying intraepithelial lymphocytes and subepithelial collagen band in microscopic colitis, extracting insights into the interrelationship of lymphocytic and collagenous colitis. Annals of Diagnostic Pathology, 2021, 52, 151741.	1.3	2
6	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocrine-Related Cancer, 2021, 28, 549-561.	3.1	10
7	Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research, 2020, 26, 902-909.	7.0	29
8	Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantation. EBioMedicine, 2020, 51, 102611.	6.1	21
9	Topographical distribution of microscopic colitis and the importance of orientation of paraffin-embedded biopsies. Human Pathology, 2020, 103, 63-71.	2.0	11
10	Methodological approach to Microscopic Colitis diagnosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 621-622.	2.8	0
11	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer, 2020, 20, 99.	2.6	31
12	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports, 2019, 9, 13568.	3.3	14
13	Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Oncologist, 2019, 24, 680-687.	3.7	7
14	Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 612-616.	2.1	8
15	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	8.2	79
16	Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome data. Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.. Journal of Clinical Oncology, 2018, 36, 4071-4071.	1.6	0
17	Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Scientific Reports, 2017, 7, 41576.	3.3	9
18	Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Scientific Reports, 2017, 7, 43702.	3.3	25

#	ARTICLE	IF	CITATIONS
19	Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. <i>Aids</i> , 2017, 31, 1245-1252.	2.2	15
20	Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. <i>Molecular Oncology</i> , 2017, 11, 1263-1272.	4.6	26
21	The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , 2017, 31, 2227-2233.	2.2	27
22	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	12.6	983
23	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. <i>Gastroenterology</i> , 2016, 151, 961-972.	1.3	41
24	The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men. <i>HIV Medicine</i> , 2016, 17, 524-531.	2.2	33
25	<i>DPYD</i> Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 655.	7.1	62
26	Tankyrase Inhibition Blocks Wnt/ $\beta$ -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 644-656.	7.0	143
27	Gastrointestinal endarteropathy in adult dermatomyositis. <i>Joint Bone Spine</i> , 2016, 83, 353-354.	1.6	3
28	Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 578-578.	1.6	2
29	Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 649-649.	1.6	1
30	Towards a new paradigm of microscopic colitis: Incomplete and variant forms. <i>World Journal of Gastroenterology</i> , 2016, 22, 8459.	3.3	19
31	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3509-3509.	1.6	0
32	Myo5b knockout mice as a model of microvillus inclusion disease. <i>Scientific Reports</i> , 2015, 5, 12312.	3.3	52
33	Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. <i>Annals of Oncology</i> , 2015, 26, 438-439.	1.2	23
34	Actualizaci3n de la recomendaci3n para la determinaci3n de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2015, 48, 14-24.	0.2	1
35	Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 264-273.	2.4	11
36	Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , 2015, 29, 695-702.	2.2	40

#	ARTICLE	IF	CITATIONS
37	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4176-4187.	1.6	515
38	Detailed characterization of <i>MLH1</i> p. <i>D41H</i> and p. <i>N710D</i> variants coexisting in a Lynch syndrome family with conserved <i>MLH1</i> expression tumors. <i>Clinical Genetics</i> , 2015, 87, 543-548.	2.0	6
39	Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3602-3602.	1.6	1
40	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 587-587.	1.6	0
41	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3584-3584.	1.6	0
42	Knocking on molecular alterations in advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4063-4063.	1.6	0
43	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5458.	12.8	95
44	Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins. <i>Clinical Breast Cancer</i> , 2014, 14, 346-351.	2.4	9
45	SPROUTY2 is a $\beta$ -catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. <i>Oncogene</i> , 2014, 33, 1975-1985.	5.9	26
46	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3591-3591.	1.6	0
47	Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 4445-4452.	1.6	170
48	Brush border myosin Ia inactivation in gastric but not endometrial tumors. <i>International Journal of Cancer</i> , 2013, 132, 1790-1799.	5.1	21
49	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. <i>Clinical Cancer Research</i> , 2013, 19, 6787-6801.	7.0	80
50	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) <i>SMARCB1</i> in NENS of colorectal origin using next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4135-4135.	1.6	0
51	Brush border Myosin Ia has tumor suppressor activity in the intestine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 1530-1535.	7.1	60
52	$\beta$ -catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. <i>Nature Medicine</i> , 2012, 18, 892-901.	30.7	336
53	Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon. <i>Revista Española De Patología</i> , 2012, 45, 76-85.	0.2	6
54	Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2062-2071.	4.1	77

#	ARTICLE	IF	CITATIONS
55	Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment.. Journal of Clinical Oncology, 2012, 30, e21021-e21021.	1.6	0
56	SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene, 2010, 29, 4800-4813.	5.9	63
57	Risk factors for positive findings in patients with highâ€grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmetteâ€GuÃ©rin therapy and the decision for a repeat TUR. BJU International, 2010, 105, 202-207.	2.5	36
58	Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. Clinical Cancer Research, 2010, 16, 2375-2382.	7.0	35
59	The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis. Cancer Research, 2009, 69, 7430-7438.	0.9	58
60	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 2009, 28, 803-814.	5.9	385
61	p16INK4a Immunostaining Identifies Occult CIN Lesions in HPV-positive Women. International Journal of Gynecological Pathology, 2009, 28, 90-97.	1.4	48
62	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study. Radiotherapy and Oncology, 2008, 89, 263-269.	0.6	13
63	Tumor trofoblÃ¡stico epitelioides de presentaciÃ³n en la posmenopausia. Progresos En Obstetricia Y Ginecologia, 2007, 50, 116-120.	0.0	0
64	p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2006, 30, 1347-1356.	3.7	150
65	Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. Cancer, 2004, 100, 950-957.	4.1	198
66	Expression of somatostatin receptor types 1â€“5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 461-475.	2.8	287